UCB通过收购Meizler Biopharma的多数股权进入巴西市场

Pharmadeals Review Pub Date : 2012-08-06 DOI:10.3833/PDR.V2012I6.1751

Heather Cartwright

{"title":"UCB通过收购Meizler Biopharma的多数股权进入巴西市场","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1751","DOIUrl":null,"url":null,"abstract":"UCB Pharma has agreed to acquire a 51% majority stake in privately held Meizler Biopharma in order to make a direct entry into the Brazilian pharmaceutical market. Although the specific financial details of the transaction were not disclosed, Meizler’s owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% in the future. The deal is the latest example of a global pharmaceutical company targeting Brazil for expansion.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"UCB Accesses Brazilian Market by Acquiring Majority Stake in Meizler Biopharma\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I6.1751\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"UCB Pharma has agreed to acquire a 51% majority stake in privately held Meizler Biopharma in order to make a direct entry into the Brazilian pharmaceutical market. Although the specific financial details of the transaction were not disclosed, Meizler’s owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% in the future. The deal is the latest example of a global pharmaceutical company targeting Brazil for expansion.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I6.1751\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I6.1751","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

UCB Pharma已同意收购私人持有的Meizler Biopharma 51%的多数股权，以便直接进入巴西制药市场。虽然交易的具体财务细节没有披露，但Meizler的所有者有权获得与业绩相关的里程碑付款，UCB可以选择在未来购买剩余的49%。这笔交易是全球制药公司瞄准巴西扩张的最新例子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

UCB Accesses Brazilian Market by Acquiring Majority Stake in Meizler Biopharma

UCB Pharma has agreed to acquire a 51% majority stake in privately held Meizler Biopharma in order to make a direct entry into the Brazilian pharmaceutical market. Although the specific financial details of the transaction were not disclosed, Meizler’s owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% in the future. The deal is the latest example of a global pharmaceutical company targeting Brazil for expansion.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量